Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

Published on
Journal: F1000Research
[저자] Shinta Oktya Wardhani, Jonny Karunia Fajar, Laksmi Wulandari, Gatot Soegiarto, Yeni Purnamasari, Anisa Asmiragani, Helnida Anggun Maliga, Muhammad Ilmawan, Gloriana Seran, Dheka Sapti Iskandar, Conchita Emiliana Ndapa, Viviana Hamat, Rafika Ajeng Wahyuni, Linda Oktaviana Suci Cyntia, Feronika Maryanti Maarang, Yosef Andrian Beo, Olivera Agnes Adar, Iraky Mardya Rakhmadhan, Emilia Tiara Shantikaratri, Ayu Sekarani Damana Putri, Rizqa Wahdini, Endang Pati Broto, Agnes Wanda Suwanto, Fredo Tamara, Aditya Indra Mahendra, Eden Suryoiman Winoto, Pratista Adi Krisna, Harapan Harapan, Guilherme Welter Wendt, Guilherme Welter Wendt, Jonny Fajar, Morteza Arab-Zozani, Morteza Arab-Zozani
[Category] COVID-19, MERS,
PMC URL    [DOI] 10.12688/f1000research.36396.3    
[Article Type] Research Article
[Source] PMC

Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non – RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.

All Keywords
【저자키워드】 COVID-19, convalescent plasma, passive immunization, Mortality, outcomes, 【초록키워드】 Randomized controlled trial, Treatment, coronavirus disease, Efficacy, therapy, severe COVID-19, Prospective Study, risk, heterogeneity, RCT, Research, Patient, plasma, mortality rate, Cross-sectional studies, COVID-19 patients, retrospective, Analysis, CCP, Web of Science, higher risk, standard treatment, Egger test, FIVE, articles, treated, searched, reduce, Jadad scale, patients treated, were assessed, 【제목키워드】 Meta-analysis, risk, Patient,